[go: up one dir, main page]

BRPI0911048A2 - formulações líquidas tamponadas de gdf-5 - Google Patents

formulações líquidas tamponadas de gdf-5

Info

Publication number
BRPI0911048A2
BRPI0911048A2 BRPI0911048A BRPI0911048A BRPI0911048A2 BR PI0911048 A2 BRPI0911048 A2 BR PI0911048A2 BR PI0911048 A BRPI0911048 A BR PI0911048A BR PI0911048 A BRPI0911048 A BR PI0911048A BR PI0911048 A2 BRPI0911048 A2 BR PI0911048A2
Authority
BR
Brazil
Prior art keywords
gdf
liquid formulations
buffered liquid
buffered
formulations
Prior art date
Application number
BRPI0911048A
Other languages
English (en)
Inventor
Dongling Su
Julius Lopez
Original Assignee
Atrm Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Atrm Llc filed Critical Atrm Llc
Publication of BRPI0911048A2 publication Critical patent/BRPI0911048A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI0911048A 2008-04-14 2009-04-08 formulações líquidas tamponadas de gdf-5 BRPI0911048A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4451808P 2008-04-14 2008-04-14
PCT/US2009/039925 WO2009129101A1 (en) 2008-04-14 2009-04-08 Liquid buffered gdf-5 formulations

Publications (1)

Publication Number Publication Date
BRPI0911048A2 true BRPI0911048A2 (pt) 2015-12-29

Family

ID=40886732

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0911048A BRPI0911048A2 (pt) 2008-04-14 2009-04-08 formulações líquidas tamponadas de gdf-5

Country Status (8)

Country Link
US (1) US7947649B2 (pt)
EP (1) EP2276458A1 (pt)
JP (1) JP5599778B2 (pt)
CN (1) CN102026619A (pt)
AU (1) AU2009236459B2 (pt)
BR (1) BRPI0911048A2 (pt)
CA (1) CA2720845A1 (pt)
WO (1) WO2009129101A1 (pt)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007234612B2 (en) * 2006-12-14 2013-06-27 Johnson & Johnson Regenerative Therapeutics, Llc Protein stabilization formulations
AU2008255016B2 (en) * 2007-05-15 2013-05-09 Stryker Corporation Concentrated protein preparations of bone morphogenetic proteins and methods of use thereof
US7678764B2 (en) 2007-06-29 2010-03-16 Johnson & Johnson Regenerative Therapeutics, Llc Protein formulations for use at elevated temperatures
CN101801405A (zh) 2007-08-07 2010-08-11 先进科技及再生医学有限责任公司 包含于酸性水溶液中的gdf-5的蛋白质配方
WO2011109415A2 (en) * 2010-03-02 2011-09-09 Amgen Inc. Reducing viscosity of pharmaceutical formulations
EP2898890B1 (en) 2010-03-31 2019-08-21 Stabilitech Biopharma Ltd Stabilisation of viral particles
WO2011121301A1 (en) 2010-03-31 2011-10-06 Stabilitech Ltd Excipients for stabilising viral particles, polypeptides or biological material
US9845489B2 (en) 2010-07-26 2017-12-19 Biomatrica, Inc. Compositions for stabilizing DNA, RNA and proteins in saliva and other biological samples during shipping and storage at ambient temperatures
EP2598660B1 (en) 2010-07-26 2017-03-15 Biomatrica, INC. Compositions for stabilizing dna, rna and proteins in blood and other biological samples during shipping and storage at ambient temperatures
JP5837930B2 (ja) * 2010-07-30 2015-12-24 ビオファーム・ゲゼルシャフト・ツァ・ビオテヒノロジッシェン・エントヴィックルング・フォン・ファルマカ・エムベーハー 創傷の治癒を加速する医薬送達装置及び増殖因子製剤
GB201117233D0 (en) 2011-10-05 2011-11-16 Stabilitech Ltd Stabilisation of polypeptides
FR2994390B1 (fr) 2012-08-10 2014-08-15 Adocia Procede d'abaissement de la viscosite de solutions de proteines a concentration elevee
EP2934572A4 (en) 2012-12-20 2016-11-23 Biomatrica Inc FORMULATIONS AND METHODS FOR STABILIZING PCR REAGENTS
US20150150983A1 (en) * 2013-12-02 2015-06-04 Depuy Mitek, Llc Intra-articular Formulations and Methods for Treatment of Osteoarthritis
GB201406569D0 (en) 2014-04-11 2014-05-28 Stabilitech Ltd Vaccine compositions
JP6669672B2 (ja) * 2014-06-10 2020-03-18 バイオマトリカ，インク． 周囲温度における血液サンプル中の変性されていないポリペプチド、核酸、およびエキソソームの安定化
WO2015191632A1 (en) 2014-06-10 2015-12-17 Biomatrica, Inc. Stabilization of thrombocytes at ambient temperatures
US11357857B2 (en) 2014-06-20 2022-06-14 Comera Life Sciences, Inc. Excipient compounds for protein processing
WO2015196091A1 (en) 2014-06-20 2015-12-23 Reform Biologics, Llc Viscosity-reducing excipient compounds for protein formulations
US10478498B2 (en) 2014-06-20 2019-11-19 Reform Biologics, Llc Excipient compounds for biopolymer formulations
JP6827048B2 (ja) 2015-12-08 2021-02-10 バイオマトリカ，インク． 赤血球沈降速度の低下
GB2562241B (en) 2017-05-08 2022-04-06 Stabilitech Biopharma Ltd Vaccine compositions
CN116898955A (zh) * 2017-09-22 2023-10-20 旭化成制药株式会社 稳定性优异的含有特立帕肽的液态药物组合物
US11324806B2 (en) 2018-10-19 2022-05-10 Warsaw Orthopedic, Inc. Sustained delivery of a growth differentiation factor
CN116478268B (zh) * 2023-05-17 2025-04-25 重庆医科大学附属第三医院(捷尔医院） Bmp2蛋白保护液、bmp2蛋白制剂及其制备方法
CN119055588B (zh) * 2024-11-06 2025-02-18 黑龙江中桂制药有限公司 一种左卡尼汀液体制剂及制备方法

Family Cites Families (150)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2931802A (en) 1958-04-30 1960-04-05 Eastman Kodak Co Mixed esters of glucose and sucrose
US4120810A (en) 1974-10-07 1978-10-17 Palmer David A Paint remover with improved safety characteristics
WO1987000196A1 (en) 1985-07-09 1987-01-15 Quadrant Bioresources Limited Protection of proteins and the like
US5013649A (en) 1986-07-01 1991-05-07 Genetics Institute, Inc. DNA sequences encoding osteoinductive products
WO1990011366A1 (en) 1989-03-28 1990-10-04 Genetics Institute, Inc. Osteoinductive compositions
IL83003A (en) 1986-07-01 1995-07-31 Genetics Inst Osteoinductive factors
US5266683A (en) 1988-04-08 1993-11-30 Stryker Corporation Osteogenic proteins
US5011691A (en) 1988-08-15 1991-04-30 Stryker Corporation Osteogenic devices
US4892319A (en) * 1988-07-20 1990-01-09 Johnson Ii Theodore D Word game
US5202311A (en) 1988-08-19 1993-04-13 Children's Medical Center Corporation Stabilized fgf composition
US5284756A (en) 1988-10-11 1994-02-08 Lynn Grinna Heterodimeric osteogenic factor
USRE38385E1 (en) 1989-02-16 2004-01-13 Nektar Therapeutics Storage of materials
JPH06500991A (ja) 1990-05-16 1994-01-27 ジェネティックス・インスティテュート・インコーポレイテッド 骨および軟骨誘導蛋白質
AU666291B2 (en) 1990-06-15 1996-02-08 Carnegie Institution Of Washington Gdf-1
US5231169A (en) 1990-10-17 1993-07-27 Norian Corporation Mineralized collagen
US5318898A (en) 1991-04-02 1994-06-07 Genetics Institute, Inc. Production of recombinant bone-inducing proteins
US6287816B1 (en) 1991-06-25 2001-09-11 Genetics Institute, Inc. BMP-9 compositions
WO1993009229A1 (en) 1991-11-04 1993-05-13 Genetics Institute, Inc. Recombinant bone morphogenetic protein heterodimers, compositions and methods of use
EP0625989B1 (en) 1992-02-12 2000-01-19 BIOPHARM GESELLSCHAFT ZUR BIOTECHNOLOGISCHEN ENTWICKLUNG VON PHARMAKA mbH Dna sequences encoding novel growth/differentiation factors
US6171584B1 (en) 1992-02-12 2001-01-09 Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Von Pharmaka Mbh Method of treatment with growth/differentiation factors of the TGF-β family
JPH08503198A (ja) 1992-11-03 1996-04-09 クリエイティブ バイオモレキュルズ，インコーポレイテッド Ｏｐ−３誘導形態形成
WO1994015949A1 (en) 1993-01-12 1994-07-21 Johns Hopkins University School Of Medicine Growth differentiation factor-5
WO1994015965A1 (en) 1993-01-12 1994-07-21 Johns Hopkins University School Of Medicine Growth differentiation factor-3
CA2153653C (en) 1993-01-12 2010-12-07 Se-Jin Lee Growth differentiation factor-9
ATE197550T1 (de) 1993-02-23 2000-12-15 Genentech Inc Stabilisierung von mit organischen lösungsmittel behandelten polypeptiden mit einem hilfsstoff
WO1994021681A1 (en) 1993-03-19 1994-09-29 Johns Hopkins University School Of Medicine Growth differentiation factor-8
CA2161807A1 (en) 1993-05-12 1994-11-24 Anthony J. Celeste Bmp-10 compositions
ATE258984T1 (de) 1993-05-12 2004-02-15 Inst Genetics Llc Bmp-11 zusammensetzungen
US5770444A (en) 1993-07-09 1998-06-23 The Johns Hopkins University School Of Medicine Growth differentiation factor-6
US6764994B1 (en) 1993-08-10 2004-07-20 Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Von Pharmaka Mbh Growth/differential factor of the TGF-B family
IL110589A0 (en) 1993-08-10 1994-11-11 Bioph Biotech Entw Pharm Gmbh Growth/differentiation factor of the TGF- beta family
US5385887A (en) * 1993-09-10 1995-01-31 Genetics Institute, Inc. Formulations for delivery of osteogenic proteins
WO1995010539A1 (en) 1993-10-08 1995-04-20 The Johns Hopkins University School Of Medicine Growth differentiation factor-10
DE4334646C1 (de) 1993-10-12 1994-09-29 Quinting Friedhelm Durchsichtige Analog-Zeituhr
AU689184B2 (en) 1993-12-07 1998-03-26 Genetics Institute, Llc BMP-12, BMP-13 and tendon-inducing compositions thereof
US5955448A (en) 1994-08-19 1999-09-21 Quadrant Holdings Cambridge Limited Method for stabilization of biological substances during drying and subsequent storage and compositions thereof
US5516645A (en) * 1994-04-25 1996-05-14 Johnson & Johnson Clinical Diagnostics, Inc. Immunoassay analytical elements containing vanadium IV(V+4)ions
IL114397A0 (en) 1994-07-01 1995-10-31 Bioph Biotech Entw Pharm Gmbh Growth/differentiation factor of the TGF-beta-family
EP0776337B1 (en) 1994-07-08 2005-09-21 The Johns Hopkins University School Of Medicine Growth differentiation factor-11
AU1120295A (en) 1994-11-07 1996-05-31 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Cartilage-derived morphogenetic proteins
US6165981A (en) 1995-03-07 2000-12-26 Dade Behring Inc. Stabilizing solutions for proteins and peptides
ATE325131T1 (de) 1995-04-19 2006-06-15 Bioph Biotech Entw Pharm Gmbh Neues protein und verfahren zu dessen herstellung
GB9508691D0 (en) 1995-04-28 1995-06-14 Pafra Ltd Stable compositions
US5635372A (en) 1995-05-18 1997-06-03 Genetics Institute, Inc. BMP-15 compositions
JPH11507032A (ja) 1995-06-05 1999-06-22 ジェネテイックス・インスティテュート・インコーポレイテッド 結合組織の付着の治癒および修復のための方法および組成物
US5747058A (en) 1995-06-07 1998-05-05 Southern Biosystems, Inc. High viscosity liquid controlled delivery system
US7833543B2 (en) 1995-06-07 2010-11-16 Durect Corporation High viscosity liquid controlled delivery system and medical or surgical device
US5968542A (en) 1995-06-07 1999-10-19 Southern Biosystems, Inc. High viscosity liquid controlled delivery system as a device
US5859286A (en) * 1995-06-09 1999-01-12 Nippon Shokubai Co., Ltd. Monomer, polymer of the same, and composition containing the polymer
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US5776193A (en) 1995-10-16 1998-07-07 Orquest, Inc. Bone grafting matrix
US5770700A (en) 1996-01-25 1998-06-23 Genetics Institute, Inc. Liquid factor IX formulations
JP2000506165A (ja) 1996-03-04 2000-05-23 ザ ペン ステイト リサーチ ファウンデーション 細胞インターナリゼーションを増強するための物質および方法
KR20000064752A (ko) * 1996-03-22 2000-11-06 더 제네랄 호스피탈 코포레이션 중추신경계허혈또는외상의발현후폴리펩티드성장인자를투여하는방법
ZA9711580B (en) 1996-12-25 1999-09-23 Hoechst Marion Roussel Ltd Process for the production of purified dimeric bone morphogenetic factors.
US5866165A (en) 1997-01-15 1999-02-02 Orquest, Inc. Collagen-polysaccharide matrix for bone and cartilage repair
US20040132653A1 (en) 1997-01-30 2004-07-08 Biopharm Gmbh Lyophilized composition of bone morphogenetic factor human MP52
AU6267798A (en) 1997-02-07 1998-08-26 Stryker Corporation Matrix-free osteogenic devices, implants and methods of use thereof
US7041641B2 (en) 1997-03-20 2006-05-09 Stryker Corporation Osteogenic devices and methods of use thereof for repair of endochondral bone and osteochondral defects
US6051558A (en) 1997-05-28 2000-04-18 Southern Biosystems, Inc. Compositions suitable for controlled release of the hormone GnRH and its analogs
US6991790B1 (en) 1997-06-13 2006-01-31 Genentech, Inc. Antibody formulation
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US6936582B1 (en) 1997-09-09 2005-08-30 Curis, Inc. Synergistic effects of OP/BMP morphogens and GDNF/NGF neurotrophic factors
US6541606B2 (en) 1997-12-31 2003-04-01 Altus Biologics Inc. Stabilized protein crystals formulations containing them and methods of making them
JP4221078B2 (ja) 1998-07-09 2009-02-12 株式会社林原生物化学研究所 トレハロース２含水結晶とその製造方法並びに用途
ES2253851T3 (es) 1998-08-07 2006-06-01 Curis, Inc. Composicion farmaceutica estable de proteinas hedgehog y uso de la misma.
US7572440B2 (en) 1999-07-30 2009-08-11 Stryker Corporation Method for repairing a defect in an intervertebral disc
US6958149B2 (en) 1998-10-06 2005-10-25 Stryker Corporation Repair of larynx, trachea, and other fibrocartilaginous tissues
US6727224B1 (en) 1999-02-01 2004-04-27 Genetics Institute, Llc. Methods and compositions for healing and repair of articular cartilage
US6969404B2 (en) 1999-10-08 2005-11-29 Ferree Bret A Annulus fibrosis augmentation methods and apparatus
US6419702B1 (en) 1999-08-13 2002-07-16 Bret A. Ferree Treating degenerative disc disease through transplantation of the nucleus pulposis
US6340369B1 (en) 1999-08-13 2002-01-22 Bret A. Ferree Treating degenerative disc disease with harvested disc cells and analogues of the extracellular matrix
US6288043B1 (en) * 1999-06-18 2001-09-11 Orquest, Inc. Injectable hyaluronate-sulfated polysaccharide conjugates
US6648918B2 (en) 1999-08-13 2003-11-18 Bret A. Ferree Treating degenerative disc disease through the transplantation of dehydrated tissue
US6685695B2 (en) 1999-08-13 2004-02-03 Bret A. Ferree Method and apparatus for providing nutrition to intervertebral disc tissue
US6352557B1 (en) 1999-08-13 2002-03-05 Bret A. Ferree Treating degenerative disc disease through transplantion of extracellular nucleus pulposus matrix and autograft nucleus pulposus cells
US6755863B2 (en) 1999-10-08 2004-06-29 Bret A. Ferree Rotator cuff repair using engineered tissues
US6344058B1 (en) 1999-08-13 2002-02-05 Bret A. Ferree Treating degenerative disc disease through transplantation of allograft disc and vertebral endplates
US7435260B2 (en) 1999-08-13 2008-10-14 Ferree Bret A Use of morphogenetic proteins to treat human disc disease
US6454804B1 (en) 1999-10-08 2002-09-24 Bret A. Ferree Engineered tissue annulus fibrosis augmentation methods and apparatus
US6793677B2 (en) 1999-08-13 2004-09-21 Bret A. Ferree Method of providing cells and other biologic materials for transplantation
US6645247B2 (en) 1999-10-08 2003-11-11 Bret A. Ferree Supplementing engineered annulus tissues with autograft of allograft tendons
US6648920B2 (en) 1999-10-08 2003-11-18 Bret A. Ferree Natural and synthetic supplements to engineered annulus and disc tissues
US20030026788A1 (en) 1999-10-08 2003-02-06 Ferree Bret A. Use of extracellular matrix tissue to preserve cultured cell phenotype
US6648919B2 (en) 1999-10-14 2003-11-18 Bret A. Ferree Transplantation of engineered meniscus tissue to the intervertebral disc
EP1244388B1 (en) 1999-12-06 2007-01-17 Warsaw Orthopedic, Inc. Intervertebral disc treatment device
EP1274459B1 (en) 2000-04-19 2005-11-16 Genentech, Inc. Sustained release formulations comprising growth hormone
US20030185812A1 (en) 2000-06-30 2003-10-02 Ferree Bret A. Method of treating dural leaks with platelet-rich plasma (PRP)
US20020032155A1 (en) 2000-06-30 2002-03-14 Ferree Bret A. Method of treating disc herniation and disc degeneration with concentrated growth and differentiation factors
US6656492B2 (en) 2000-06-30 2003-12-02 Yamanouchi Pharmaceutical Co., Ltd. Quick disintegrating tablet in buccal cavity and manufacturing method thereof
US20020173770A1 (en) 2001-05-16 2002-11-21 Flory Alan R. Adhesive delivery system
AU2002320122B2 (en) 2001-06-21 2007-07-26 Genentech, Inc. Sustained release formulation
CA2460690A1 (en) 2001-10-05 2003-04-17 Intermune, Inc. Method of treating hepatitis virus infection with a multiphasic interferon delivery profile
US20060024346A1 (en) 2004-07-29 2006-02-02 Brody Richard S Stabilization of biologically active proteins with mixtures of polysaccharides and amino acid based compounds
PT1448246E (pt) * 2001-11-19 2005-11-30 Scil Technology Gmbh Aparelho com revestimento homogeneo com propriedades osteoindutoras e osteocondutoras
TWI265654B (en) 2001-11-21 2006-11-01 Polyfuel Inc Catalyst agglomerates for membrane electrode assemblies
AU2002235518A1 (en) 2002-02-04 2003-09-02 Bret A. Ferree Treating degenerative disc disease through transplantation of allograft disc
NZ535008A (en) 2002-02-08 2005-09-30 Alkermes Inc Polymer-based compositions for sustained release
US6780324B2 (en) 2002-03-18 2004-08-24 Labopharm, Inc. Preparation of sterile stabilized nanodispersions
US20030192554A1 (en) 2002-04-11 2003-10-16 Ferree Bret A. Methods and apparatus for adhering musculoskeletal tissues
US6981991B2 (en) 2002-06-27 2006-01-03 Ferree Bret A Arthroplasty devices configured to reduce shear stress
US20040022771A1 (en) 2002-07-30 2004-02-05 Ferree Bret A. Transfer of cells, tissue, and other substances to bone
US7744651B2 (en) 2002-09-18 2010-06-29 Warsaw Orthopedic, Inc Compositions and methods for treating intervertebral discs with collagen-based materials
NZ539478A (en) 2002-10-25 2006-05-26 Akzo Nobel Nv Composition comprising cefquinome in a prolonged release vehicle of oil and aluminium distearate, which results in a prolonged duration in the blood plasma
EP1462126A1 (en) * 2003-03-28 2004-09-29 BIOPHARM GESELLSCHAFT ZUR BIOTECHNOLOGISCHEN ENTWICKLUNG VON PHARMAKA mbH Improved Osteoinductive Materials
JP4869064B2 (ja) 2003-04-04 2012-02-01 ジェネンテック， インコーポレイテッド 高濃度抗体及びタンパク質製剤
DE10333835A1 (de) 2003-07-24 2005-03-10 Gruenenthal Gmbh 6-Dimethylaminomethyl-1-(3-methoxy-phenyl)-cyclohexane-1,3-diol enthaltendes Arzneimittel mit verzögerter Wirkstofffreisetzung
US7375077B2 (en) 2003-09-19 2008-05-20 The Board Of Trustees Of The University Of Illinois In vivo synthesis of connective tissues
US7879102B2 (en) 2003-09-30 2011-02-01 Depuy Acromed, Inc. Method for treatment of defects in the intervertebral disc
US20050148512A1 (en) 2003-11-10 2005-07-07 Angiotech International Ag Medical implants and fibrosis-inducing agents
SI21639A (sl) 2003-12-23 2005-06-30 LEK farmacevtska dru�ba d.d. Farmacevtski pripravek, ki vsebuje nemicelarne sulfobetaine
KR20070010046A (ko) 2004-04-06 2007-01-19 제넨테크, 인크. Ｄｒ5 항체 및 그의 용도
US20070269477A1 (en) 2004-05-05 2007-11-22 Igo Stephen R Heart Treatment Method
AU2005247440B2 (en) 2004-05-25 2011-09-29 Stryker Corporation Use of morphogenic proteins for treating cartilage defects
EP1604693A1 (en) 2004-06-09 2005-12-14 Scil Technology GmbH In situ forming scaffold, its manufacturing and use
FR2871457B1 (fr) 2004-06-10 2006-08-11 Giat Ind Sa Composition pyrotechnique ayant une tenue mecanique amelioree
US8105983B2 (en) 2005-03-29 2012-01-31 The Regents Of The University Of California High-throughput method for optimum solubility screening for homogeneity and crystallization of proteins
BRPI0611901A2 (pt) 2005-06-14 2012-08-28 Amgen, Inc composição, liofilizado, kit, e, processo para preparar uma composição
US20060286289A1 (en) 2005-06-15 2006-12-21 Rita Prajapati Method of intraoperative coating therapeutic agents onto sutures
US20060287676A1 (en) 2005-06-15 2006-12-21 Rita Prajapati Method of intra-operative coating therapeutic agents onto sutures, composite sutures and methods of use
US20060286171A1 (en) 2005-06-17 2006-12-21 Tianhong Zhou Bone morphogenetic protein formulations
US7648764B2 (en) * 2005-06-30 2010-01-19 Uchicago Argonne, Llc Two-piece container seal and method of manufacture
CA2915270C (en) 2005-08-05 2017-07-11 Amgen Inc. Stable aqueous protein or antibody pharmaceutical formulations and their preparation
CA2621786A1 (en) 2005-08-29 2007-03-08 Tuo Jin Polysaccharide microparticles containing biological agents: there preparation and applications
US8249724B2 (en) 2005-08-31 2012-08-21 Cochlear Limited Elongate implantable carrier member having an embedded stiffener
CA2627907C (en) 2005-11-01 2014-06-17 Osteotech, Inc. Osteoinductive composition comprising osteoinductive factors recovered from mineralized bone and a carrier
AU2006330858A1 (en) 2005-12-21 2007-07-05 Wyeth Protein formulations with reduced viscosity and uses thereof
US20070178159A1 (en) 2006-01-30 2007-08-02 Alza Corporation In-Situ Forming Porous Scaffold
EP1880731A1 (en) 2006-07-18 2008-01-23 BIOPHARM GESELLSCHAFT ZUR BIOTECHNOLOGISCHEN ENTWICKLUNG VON PHARMAKA mbH Human growth and differentiation factor GDF-5
US20080098614A1 (en) 2006-10-03 2008-05-01 Wyeth Lyophilization methods and apparatuses
EP2078073B1 (en) 2006-10-12 2013-07-24 Ethicon, Inc. Kidney-derived cells and methods of use in tissue repair and regeneration
EP1915986A1 (en) 2006-10-23 2008-04-30 BIOPHARM GESELLSCHAFT ZUR BIOTECHNOLOGISCHEN ENTWICKLUNG VON PHARMAKA mbH Lipid growth factor formulations
AU2007234612B2 (en) 2006-12-14 2013-06-27 Johnson & Johnson Regenerative Therapeutics, Llc Protein stabilization formulations
US8048857B2 (en) 2006-12-19 2011-11-01 Warsaw Orthopedic, Inc. Flowable carrier compositions and methods of use
JP5452230B2 (ja) 2006-12-21 2014-03-26 ストライカー コーポレイション 生物学的因子の結晶、高分子ゲルおよび粒子懸濁液を含む持続放出処方物
GB2446653A (en) 2007-02-16 2008-08-20 Inion Ltd Osteogenic compounds
GB2446652A (en) 2007-02-16 2008-08-20 Inion Ltd Osteogenic compounds
US20080234727A1 (en) 2007-03-22 2008-09-25 Venkat Garigapati Novel Carriers For Coating Growth Factors Onto Sutures
AU2008255016B2 (en) 2007-05-15 2013-05-09 Stryker Corporation Concentrated protein preparations of bone morphogenetic proteins and methods of use thereof
US7883664B2 (en) 2007-06-27 2011-02-08 University Of North Carolina At Charlotte Microwave drying process for vitrification of biologics
US7678764B2 (en) 2007-06-29 2010-03-16 Johnson & Johnson Regenerative Therapeutics, Llc Protein formulations for use at elevated temperatures
JP5362715B2 (ja) * 2007-06-29 2013-12-11 アドバンスト・テクノロジーズ・アンド・リジェネレイティブ・メディスン・エルエルシー 高温で使用するためのｇｄｆ−５を含む液体タンパク質製剤
US20110014676A1 (en) 2007-06-29 2011-01-20 Battelle Memorial Institute Protein stabilization
EP2019117A1 (en) 2007-07-27 2009-01-28 BIOPHARM GESELLSCHAFT ZUR BIOTECHNOLOGISCHEN ENTWICKLUNG VON PHARMAKA mbH Optimized purification process of recombinant growth factor protein
FR2919188B1 (fr) 2007-07-27 2010-02-26 Proteins & Peptides Man Complexes entre un polymere amphiphile et une proteine osteogenique appartenant a la famille des bmps
GB2451451A (en) 2007-07-30 2009-02-04 Inion Ltd Osteogenic compounds
CN101801405A (zh) 2007-08-07 2010-08-11 先进科技及再生医学有限责任公司 包含于酸性水溶液中的gdf-5的蛋白质配方
US8420081B2 (en) 2007-11-30 2013-04-16 Abbvie, Inc. Antibody formulations and methods of making same
WO2009140162A1 (en) 2008-05-15 2009-11-19 Baxter International Inc. Stable pharmaceutical formulations
ES2968301T3 (es) 2008-08-05 2024-05-08 Wyeth Llc Liofilización por encima del colapso

Also Published As

Publication number Publication date
AU2009236459B2 (en) 2013-07-25
US20090259023A1 (en) 2009-10-15
AU2009236459A1 (en) 2009-10-22
JP5599778B2 (ja) 2014-10-01
US7947649B2 (en) 2011-05-24
WO2009129101A1 (en) 2009-10-22
JP2011516608A (ja) 2011-05-26
EP2276458A1 (en) 2011-01-26
CA2720845A1 (en) 2009-10-22
CN102026619A (zh) 2011-04-20

Similar Documents

Publication Publication Date Title
BRPI0911048A2 (pt) formulações líquidas tamponadas de gdf-5
BRPI0910515A2 (pt) composição líquida
BRPI0921298A2 (pt) dispositivo de exibição
BRPI0822306A2 (pt) Dispositivo de exibição
BRPI0818324A2 (pt) formulações líquidas de lh
BRPI0909644A2 (pt) dispositivo de foto-epilação
BRPI0922730A2 (pt) formulação de anticorpo
BRPI0912271A2 (pt) co-autoria estruturada
BRPI0909375A2 (pt) Moduladores de receptores de quimiocinas
DK2114143T3 (da) Flydende sulfonylurea-herbicidformuleringer
DK2200752T3 (da) Doseringsindretning
BRPI0913252A2 (pt) dispositivo de display
EP2504020A4 (en) Daptomycin FORMULATIONS
BRPI0911026A2 (pt) dispositivo de difusão de líquido com borrifadores intercambiáves
EP2383711A4 (en) DRIVER ASSISTANCE DEVICE
BRPI0906734A2 (pt) Dispositivo de virola
BRPI0915210A2 (pt) dispositivo de exibição
DK2323933T3 (da) Stableenhed
DK2342060T3 (da) Doseringsindretning
BRPI0923891A2 (pt) dispositivo de dosagem
BRPI0918475A2 (pt) dispositivo de display
DE112009002275A5 (de) Anzeigevorrichtung
ATE520307T1 (de) Stabilisierte malathion-mikrokapselformulierungen
PT2376075E (pt) Formulações nasais de metoclopramida
BRPI0915364A2 (pt) dispositivo de visualização

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]